Quality of life analysis of patients treated with cetuximab or cisplatin for locoregionally advanced squamous cell carcinoma of head and neck in the United States

Aggarwal, Himani; Punekar, Rajeshwari S.; Li, Li; Carter, Gebra Cuyun; Walker, Mark S.

doi:10.1186/s12955-020-01424-x

Table 2 Linear mixed models of General Physical Symptoms, Treatment Side Effects, and Acute Distress

From: Quality of life analysis of patients treated with cetuximab or cisplatin for locoregionally advanced squamous cell carcinoma of head and neck in the United States

	General Physical Symptoms^a		Treatment Side Effects^b		Acute Distress^c
Effect	Estimate (SE)	P-value	Estimate (SE)	P-value	Estimate (SE)	P-value
Intercept	58.50 (8.141)	< 0.0001	59.60 (5.877)	< 0.0001	60.10 (9.236)	< 0.0001
Time (months) since diagnosis	− 0.10 (0.040)	0.018	− 0.12 (0.024)	< 0.0001	− 0.17 (0.039)	< 0.0001
Treatment: cetuximab±RT (vs. cisplatin±RT)	1.19 (1.667)	0.475	−0.32 (1.221)	0.792	5.77 (2.013)	0.004
Treatment* time since diagnosis	0.13 (0.14)	0.352	0.05 (0.084)	0.540	−0.18 (0.143)	0.205
Age at diagnosis	−0.25 (0.070)	0.001	−0.14 (0.051)	0.005	−0.27 (0.076)	0.001
Male (vs. female)	−2.42 (1.342)	0.072	−2.13 (0.974)	0.029	−6.88 (1.487)	< 0.0001
White (vs. minority/unknown)	0.41 (1.212)	0.733	−0.41 (0.883)	0.644	3.74 (1.347)	0.006
Impaired composite performance status (vs. not impaired)	1.94 (2.438)	0.427	2.01 (1.755)	0.252	−0.13 (2.700)	0.962
Weighted index of comorbid conditions	0.67 (0.641)	0.298	0.57 (0.465)	0.220	1.67 (0.714)	0.020
Smoking status: current or past (vs. never/unknown/undocumented)	2.64 (1.523)	0.083	0.40 (1.102)	0.715	3.98 (1.687)	0.019
Alcohol status	–	0.534	–	0.176	–	0.055
Current or past abuse (vs. never/unknown/undocumented)	0.89 (1.591)	0.576	1.05 (1.153)	0.363	2.09 (1.761)	0.235
Current or past use (vs. never/unknown/undocumented)	−0.66 (1.302)	0.614	−0.82 (0.944)	0.386	−1.61 (1.44)	0.262
Stage at start: Stage III (vs. Stage IV)	0.11 (1.156)	0.922	−0.15 (0.836)	0.854	−0.05 (1.273)	0.971
Oral (vs. non-oral)	−1.64 (3.064)	0.592	0.26 (2.249)	0.908	−3.48 (3.491)	0.319
Pharynx (vs. non-pharynx)	−0.04 (2.987)	0.989	1.88 (2.193)	0.393	−0.18 (3.406)	0.959
Larynx (vs. non-larynx)	−0.73 (3.144)	0.817	0.00 (2.314)	0.999	−2.86 (3.581)	0.425
HPV test results (positive vs. non-positive)	2.60 (3.273)	0.428	3.11 (2.354)	0.187	−5.02 (3.686)	0.174
P16 test results (positive vs. non-positive)	1.469 (1.350)	0.277	0.95 (0.977)	0.332	3.17 (1.479)	0.033
Feeding tube placement (vs. not placed)	1.066 (1.158)	0.356	0.866 (0.841)	0.304	1.26 (1.282)	0.327
BMI	−0.05 (0.093)	0.581	0.005 (0.067)	0.942	−0.06 (0.103)	0.540
Insurance	–	0.010	–	0.052	–	0.047
Only public (vs. only private)	4.85 (1.555)	0.002	2.67 (1.128)	0.018	4.50 (1.728)	0.010
Both public and private (vs. only private)	3.54 (1.458)	0.015	1.70 (1.059)	0.109	2.98 (1.617)	0.066
Other/unknown/undocumented (vs. only private)	4.395 (3.468)	0.205	4.43 (2.574)	0.086	5.09 (3.958)	0.199
US region South (vs. non-South)	4.12 (5.476)	0.452	1.167 (3.942)	0.767	3.68 (6.336)	0.561

Reference level for each comparison is in parentheses
BMI body mass index, HPV human papilloma virus, RT radiation therapy, SE standard error, US United States
^aAnalysis is based on 237 patients and 1859 observations
^bAnalysis is based on 237 patients and 1866 observations
^cAnalysis is based on 237 patients and 1596 observations
*refers to an interaction

Back to article page

ISSN: 1477-7525

Contact us

Submission enquiries: journalsubmissions@springernature.com

Health and Quality of Life Outcomes

Contact us